USP31

Summary

USP31 (ubiquitin specific peptidase 31, HGNC:20060) is a protein-coding gene on chromosome 16p12.2, encoding Ubiquitin carboxyl-terminal hydrolase 31 (Q70CQ4). Deubiquitinase that recognizes and hydrolyzes the peptide bond at the C-terminal Gly of ubiquitin.

Enables cysteine-type deubiquitinase activity. Predicted to be involved in protein deubiquitination and proteolysis. Located in nucleus.

Source: NCBI Gene 57478 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 231 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_020718

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20060
Approved symbol	USP31
Name	ubiquitin specific peptidase 31
Location	16p12.2
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1203
Ensembl gene	ENSG00000103404
Ensembl biotype	protein_coding
OMIM	619536
Entrez	57478

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000219689, ENST00000563525, ENST00000567975, ENST00000953487

RefSeq mRNA: 2 — MANE Select: NM_020718 NM_001387221, NM_020718

CCDS: CCDS10607

Canonical transcript exons

ENST00000219689 — 16 exons

Exon	Start	End
ENSE00000677549	23079946	23080171
ENSE00000677550	23073722	23073880
ENSE00001318477	23061406	23069616
ENSE00001365379	23087092	23087186
ENSE00001366994	23102319	23102463
ENSE00001367898	23108046	23108183
ENSE00001371775	23090624	23090804
ENSE00001375975	23105441	23105576
ENSE00001383579	23148638	23149452
ENSE00001385008	23087724	23087835
ENSE00001386630	23106399	23106487
ENSE00001711660	23106213	23106305
ENSE00003581647	23072045	23072197
ENSE00003718345	23082438	23082557
ENSE00003727403	23085585	23085662
ENSE00003732583	23084860	23084989

Expression profiles

Bgee: expression breadth ubiquitous, 251 present calls, max score 96.34.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.8098 / max 92.8446, expressed in 1723 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
156768	8.8098	1723

Top tissues by expression

259 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
inferior vagus X ganglion	UBERON:0005363	96.34	gold quality
secondary oocyte	CL:0000655	95.68	gold quality
cauda epididymis	UBERON:0004360	93.84	gold quality
subthalamic nucleus	UBERON:0001906	93.66	gold quality
substantia nigra pars compacta	UBERON:0001965	93.02	gold quality
substantia nigra pars reticulata	UBERON:0001966	92.91	gold quality
adult organism	UBERON:0007023	92.82	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	92.55	gold quality
dorsal plus ventral thalamus	UBERON:0001897	92.15	gold quality
lateral nuclear group of thalamus	UBERON:0002736	92.02	gold quality
nipple	UBERON:0002030	91.84	gold quality
medulla oblongata	UBERON:0001896	91.79	gold quality
middle temporal gyrus	UBERON:0002771	91.19	gold quality
superior vestibular nucleus	UBERON:0007227	91.15	gold quality
cardiac muscle of right atrium	UBERON:0003379	91.06	gold quality
postcentral gyrus	UBERON:0002581	90.95	gold quality
lateral globus pallidus	UBERON:0002476	90.85	gold quality
parietal lobe	UBERON:0001872	90.37	gold quality
ventral tegmental area	UBERON:0002691	90.32	gold quality
tibialis anterior	UBERON:0001385	89.73	silver quality
heart right ventricle	UBERON:0002080	89.62	gold quality
myocardium	UBERON:0002349	89.42	gold quality
pons	UBERON:0000988	89.36	gold quality
corpus callosum	UBERON:0002336	89.28	gold quality
Brodmann (1909) area 23	UBERON:0013554	89.07	gold quality
entorhinal cortex	UBERON:0002728	88.55	gold quality
mucosa of paranasal sinus	UBERON:0005030	88.41	gold quality
endothelial cell	CL:0000115	88.35	gold quality
skin of hip	UBERON:0001554	88.12	gold quality
Brodmann (1909) area 46	UBERON:0006483	87.78	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.85
E-CURD-10	no	830.05

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

332 targeting USP31, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4482-3P	99.98	72.50	3147

Literature-anchored findings (GeneRIF, showing 2)

• USP31 acetylation at Lys1264 is essential for its activity and cervical cancer cell growth. (PMID:34184746)
• USP31 serves as a potential biomarker for predicting prognosis and immune responses for clear cell renal cell carcinoma via single-cell and bulk RNA-sequencing. (PMID:37699648)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	usp31	ENSDARG00000074017
mus_musculus	Usp31	ENSMUSG00000063317
rattus_norvegicus	Usp31	ENSRNOG00000025793

Paralogs (71): USP2 (ENSG00000036672), USP28 (ENSG00000048028), USP36 (ENSG00000055483), USP13 (ENSG00000058056), USP33 (ENSG00000077254), USP40 (ENSG00000085982), USP48 (ENSG00000090686), USP14 (ENSG00000101557), USP11 (ENSG00000102226), USP10 (ENSG00000103194), USP42 (ENSG00000106346), USP5 (ENSG00000111667), USP4 (ENSG00000114316), USP9Y (ENSG00000114374), USP34 (ENSG00000115464), USP35 (ENSG00000118369), USP45 (ENSG00000123552), USP22 (ENSG00000124422), USP9X (ENSG00000124486), USP6 (ENSG00000129204), USP29 (ENSG00000131864), USP26 (ENSG00000134588), USP30 (ENSG00000135093), USP15 (ENSG00000135655), USP37 (ENSG00000135913), USP44 (ENSG00000136014), USP20 (ENSG00000136878), USP8 (ENSG00000138592), USP3 (ENSG00000140455), USP21 (ENSG00000143258), USP43 (ENSG00000154914), USP25 (ENSG00000155313), USP16 (ENSG00000156256), USP24 (ENSG00000162402), USP1 (ENSG00000162607), USP49 (ENSG00000164663), USP38 (ENSG00000170185), USP50 (ENSG00000170236), USP47 (ENSG00000170242), USP32 (ENSG00000170832)

Protein

Protein identifiers

Ubiquitin carboxyl-terminal hydrolase 31 — Q70CQ4 (reviewed: Q70CQ4)

Alternative names: Deubiquitinating enzyme 31, Ubiquitin thioesterase 31, Ubiquitin-specific-processing protease 31

All UniProt accessions (3): Q70CQ4, A0A087WXV9, I3L4X5

UniProt curated annotations — full annotation on UniProt →

Function. Deubiquitinase that recognizes and hydrolyzes the peptide bond at the C-terminal Gly of ubiquitin. May play a role in the regulation of NF-kappa-B signaling pathway by deubiquitinating TRAF2. (Microbial infection) Plays a positive role in foot-and-mouth disease and classical swine fever viral infection. Mechanistically, associates with internal ribosomal entry site (IRES) element within the 5’-untranslated region of viral genomes to promote translation of the virus-encoded polyprotein.

Tissue specificity. Widely expressed.

Post-translational modifications. Acetylated at Lys-1264. Acetylation decreases activity. Deacetylated by SIRT1.

Similarity. Belongs to the peptidase C19 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q70CQ4-1	1	yes
Q70CQ4-2	2

RefSeq proteins (2): NP_001374150, NP_065769* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001394	Peptidase_C19_UCH	Domain
IPR018200	USP_CS	Conserved_site
IPR028889	USP	Domain
IPR038765	Papain-like_cys_pep_sf	Homologous_superfamily
IPR050185	Ub_carboxyl-term_hydrolase	Family

Pfam: PF00443

UniProt features (43 total): compositionally biased region 17, sequence variant 7, region of interest 6, splice variant 4, sequence conflict 3, active site 2, chain 1, domain 1, modified residue 1, mutagenesis site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q70CQ4-F1	58.39	0.27

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 137 (nucleophile); 723 (proton acceptor)

Post-translational modifications (1): 1264

Mutagenesis-validated functional residues (1):

Position	Phenotype
1264	significant increases of traf2 polyubiquitination levels.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 184 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, TGACCTY_ERR1_Q2, GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_REMOVAL, GOMF_CYSTEINE_TYPE_PEPTIDASE_ACTIVITY, USF_01, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_DN, DODD_NASOPHARYNGEAL_CARCINOMA_UP, DOUGLAS_BMI1_TARGETS_UP, CHANG_IMMORTALIZED_BY_HPV31_UP, chr16p12, LIU_SOX4_TARGETS_UP, GOBP_PROTEOLYSIS, GOMF_PEPTIDASE_ACTIVITY, TCANNTGAY_SREBP1_01

GO Biological Process (2): proteolysis (GO:0006508), protein deubiquitination (GO:0016579)

GO Molecular Function (5): cysteine-type deubiquitinase activity (GO:0004843), peptidase activity (GO:0008233), cysteine-type peptidase activity (GO:0008234), hydrolase activity (GO:0016787), ubiquitin-like protein peptidase activity (GO:0019783)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
peptidase activity	2
protein metabolic process	1
cysteine-type deubiquitinase activity	1
protein modification by small protein removal	1
cysteine-type peptidase activity	1
deubiquitinase activity	1
hydrolase activity	1
catalytic activity, acting on a protein	1
catalytic activity	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

876 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
USP31	PTPRQ	Q9UMZ3	519
USP31	FBXO21	O94952	506
USP31	RBBP6	Q7Z6E9	473
USP31	ARHGEF33	A8MVX0	447
USP31	CDH23	Q9H251	421
USP31	ANO9	A1A5B4	418
USP31	GCNA	Q96QF7	411
USP31	ANO4	Q32M45	410
USP31	FGFBP3	Q8TAT2	410
USP31	ZNF592	Q92610	410
USP31	RIMKLA	Q8IXN7	403
USP31	FAM90A1	Q86YD7	399
USP31	ELP4	Q96EB1	398
USP31	USP30	Q70CQ3	396
USP31	CDC42BPB	Q9Y5S2	391

IntAct

12 interactions, top by confidence:

A	B	Type	Score
YWHAH	BLTP3B	psi-mi:“MI:2364”(proximity)	0.570
APBB1	SSPOP	psi-mi:“MI:0914”(association)	0.350
CTDSPL	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
SFN	BLTP3B	psi-mi:“MI:2364”(proximity)	0.270
YWHAB	E2F8	psi-mi:“MI:2364”(proximity)	0.270
YWHAE	E2F8	psi-mi:“MI:2364”(proximity)	0.270
YWHAH	E2F8	psi-mi:“MI:2364”(proximity)	0.270
YWHAQ	E2F8	psi-mi:“MI:2364”(proximity)	0.270
YWHAZ	E2F8	psi-mi:“MI:2364”(proximity)	0.270
YWHAG	E2F8	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (36): USP31 (Affinity Capture-MS), USP31 (Proximity Label-MS), USP31 (Reconstituted Complex), USP31 (Affinity Capture-RNA), USP31 (Proximity Label-MS), USP31 (Proximity Label-MS), USP31 (Proximity Label-MS), USP31 (Proximity Label-MS), USP31 (Proximity Label-MS), USP31 (Proximity Label-MS), USP31 (Proximity Label-MS), USP31 (Proximity Label-MS), SIRT1 (Affinity Capture-Western), USP31 (Proximity Label-MS), USP31 (Affinity Capture-MS)

ESM2 similar proteins: A0JM59, A2BGT0, A5PJS6, A5PMR2, A5PN09, A6QNM7, A7Z056, B1AY15, B1WBD7, D2HBJ8, E1C213, E7F6T8, E9QG68, O88974, P52479, Q0V9G5, Q14694, Q15047, Q1RMU2, Q28CN3, Q2KJ09, Q2NL57, Q3KR59, Q5R5Z6, Q5RED8, Q5REG5, Q5XGZ2, Q5ZJN4, Q66H62, Q6NTR6, Q6P549, Q70CQ3, Q70CQ4, Q70EK9, Q7ZUM8, Q7ZXR7, Q80TQ2, Q8BW70, Q8C0R0, Q8C2S0

Diamond homologs: A0A0R4IB93, A0JM59, A5PMR2, A5PN09, A6NNY8, A6QNM7, A7Z056, B1AY13, B1WBD7, D2HBJ8, D6RBM5, E1C213, E7F6T8, E9Q9U0, F6Z5C0, F8VPU6, F8VPZ3, M9PD06, O00507, O22207, O60079, O74442, O94269, O94966, O96612, P0C7I0, P0C8Z3, P0CAQ1, P35125, P39538, P40453, P51784, P53874, P55824, P70398, Q01988, Q09738, Q0V9G5, Q28CN3, Q2HJE4

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 13 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	7	484.5×	3e-17
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	427.5×	4e-17
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	427.5×	4e-17
Activation of BH3-only proteins	7	316.0×	4e-16
RHO GTPases activate PKNs	7	201.9×	1e-14
Intrinsic Pathway for Apoptosis	7	186.3×	2e-14
FOXO-mediated transcription	5	152.7×	4e-10
SARS-CoV-1-host interactions	7	111.8×	7e-13

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	5	152.6×	5e-09
intracellular protein localization	7	61.1×	6e-10

Disease & clinical

Clinical variants and AI predictions

ClinVar

231 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	194
Likely benign	8
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

8780 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:23072166:C:A	W789C	1.000
16:23072166:C:G	W789C	1.000
16:23072168:A:G	W789R	1.000
16:23072168:A:T	W789R	1.000
16:23073773:A:C	Y762D	1.000
16:23073778:A:G	L760P	1.000
16:23073835:T:A	D741V	1.000
16:23073851:A:G	W736R	1.000
16:23073851:A:T	W736R	1.000
16:23073867:G:C	N730K	1.000
16:23073867:G:T	N730K	1.000
16:23073873:A:C	C728W	1.000
16:23073874:C:T	C728Y	1.000
16:23079952:A:G	Y724H	1.000
16:23079955:G:C	H723D	1.000
16:23079957:C:T	G722E	1.000
16:23079977:G:C	H715Q	1.000
16:23079977:G:T	H715Q	1.000
16:23079979:G:C	H715D	1.000
16:23079990:G:T	A711D	1.000
16:23080137:A:T	V662D	1.000
16:23082444:A:C	F648L	1.000
16:23082444:A:T	F648L	1.000
16:23082445:A:G	F648S	1.000
16:23082446:A:G	F648L	1.000
16:23082447:T:A	R647S	1.000
16:23082447:T:G	R647S	1.000
16:23082448:C:G	R647T	1.000
16:23082450:C:A	K646N	1.000
16:23082450:C:G	K646N	1.000

dbSNP variants (sampled 300 via entrez): RS1000056244 (16:23091365 C>T), RS1000098619 (16:23079136 T>C,G), RS1000130111 (16:23130120 C>G), RS1000158027 (16:23121509 C>T), RS1000170636 (16:23068337 C>T), RS1000186807 (16:23150671 T>C), RS1000207550 (16:23133265 G>A), RS1000284011 (16:23096843 T>C,G), RS1000335931 (16:23103057 T>A), RS1000361927 (16:23104091 C>A,T), RS1000367090 (16:23102797 T>C), RS1000398015 (16:23144503 A>G), RS1000410289 (16:23073561 T>G), RS1000441233 (16:23064287 C>G,T), RS1000500706 (16:23129747 T>C)

Disease associations

OMIM: gene MIM:619536 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): sensorineural hearing loss disorder (MONDO:0020678)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000407	Sensorineural hearing impairment

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
FR900359	increases phosphorylation	1
testosterone enanthate	affects expression	1
triphenyl phosphate	affects expression	1
2-butenal	decreases expression	1
beta-lapachone	increases expression	1
mono-(2-ethylhexyl)phthalate	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
butyraldehyde	decreases expression	1
manganese chloride	decreases expression, increases abundance	1
K 7174	increases expression	1
abrine	increases expression	1
Sunitinib	increases expression	1
Zoledronic Acid	increases expression	1
Fulvestrant	increases methylation	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Caffeine	affects phosphorylation	1
Doxorubicin	decreases expression	1
Estradiol	increases expression	1
Ethyl Methanesulfonate	increases expression	1
Folic Acid	decreases expression	1
Formaldehyde	increases expression	1
Lead	decreases expression	1
Manganese	increases abundance, decreases expression	1
Silver	decreases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TW86	HAP1 USP31 (-) 1	Cancer cell line	Male
CVCL_TW87	HAP1 USP31 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

89 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01655212	PHASE3	TERMINATED	Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
NCT02005822	PHASE3	COMPLETED	Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
NCT03374514	PHASE3	UNKNOWN	Cochlear Electrical Impedance and the Effect of Topical Dexamethasone on Cochlear Implant Surgery
NCT02497690	PHASE2	COMPLETED	Effectiveness of Therapy Via Telemedicine Following Cochlear Implants
NCT03107871	PHASE2	ACTIVE_NOT_RECRUITING	Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants
NCT04120116	PHASE2	COMPLETED	FX-322 in Adults With Stable Sensorineural Hearing Loss
NCT05061758	PHASE2	WITHDRAWN	A Trial of LY3056480 in Patients With SNLH
NCT07364747	PHASE2	RECRUITING	Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
NCT02693704	PHASE2/PHASE3	COMPLETED	Evaluation of a Binaural Spatialization Method for Hearing Aids
NCT02882477	PHASE2/PHASE3	UNKNOWN	Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy
NCT01267994	PHASE1/PHASE2	COMPLETED	A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease
NCT01902914	PHASE1/PHASE2	UNKNOWN	Effectiveness of P02 Digital Hearing Aids
NCT02038972	PHASE1/PHASE2	COMPLETED	Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss
NCT02616172	PHASE1/PHASE2	SUSPENDED	Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss
NCT03616223	PHASE1/PHASE2	COMPLETED	FX-322 in Sensorineural Hearing Loss
NCT04129775	PHASE1/PHASE2	COMPLETED	OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
NCT04462198	PHASE1/PHASE2	COMPLETED	Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss
NCT07032038	PHASE1/PHASE2	NOT_YET_RECRUITING	First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant
NCT06025097	EARLY_PHASE1	COMPLETED	Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus.
NCT06707389	EARLY_PHASE1	NOT_YET_RECRUITING	Autologous Blood Monocyte Vesicles for the Treatment of Sudden Deafness
NCT07472023	EARLY_PHASE1	ENROLLING_BY_INVITATION	Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss
NCT00023036	Not specified	COMPLETED	Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
NCT00023049	Not specified	COMPLETED	Genetic Analysis of Hereditary Disorders of Hearing and Balance
NCT00261768	Not specified	COMPLETED	Efficacy of Digital Noise Reduction Strategies: A Hearing Aid Trial
NCT00589511	Not specified	COMPLETED	Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study
NCT00678899	Not specified	COMPLETED	Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System
NCT00787189	Not specified	COMPLETED	Study of Low Level Laser Therapy and Word Recognition in Hearing Impaired Individuals
NCT01184248	Not specified	COMPLETED	The Effect of Sound Stimulation on Pure-tone Hearing Threshold
NCT01434446	Not specified	COMPLETED	The Effect of Sound Stimulation on Hearing Ability
NCT01749592	Not specified	COMPLETED	Single-sided Deafness and Cochlear Implants
NCT01781039	Not specified	COMPLETED	Investigation of Anatomical Correlates of Speech Discrimination
NCT02082431	Not specified	COMPLETED	Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss.
NCT02093806	Not specified	UNKNOWN	Clinical Applications of Round Window Imaging Anatomy in Cochlear Implant Surgery
NCT02252601	Not specified	UNKNOWN	Evaluation of the High Frequency Digit Triplet Test in Cystic Fibrosis
NCT02584361	Not specified	UNKNOWN	Cochlear Implant and Vestibular Function.
NCT02638883	Not specified	COMPLETED	Implantation of the Cochlear™ Nucleus® Hybrid S Round Window (S-RW) in Adults
NCT02689349	Not specified	COMPLETED	Esteem New Subject Enrollment Post Approval Study
NCT02698787	Not specified	COMPLETED	Fundamental Asynchronous Stimulus Timing Sound Coding Study
NCT02798783	Not specified	COMPLETED	Enlarged Vestibular Aqueduct Registry